LSNE Announces Acquisition of PSC Biotech’s Parenteral Manufacturing Facility

23 April 2018

Lyophilization Services of New England (LSNE), a leading contract development and manufacturing organization (CDMO), today announced that it has acquired PSC Biotech’s cGMP aseptic fill finish manufacturing facility located in Madison, Wisconsin. This acquisition allows LSNE to expand its manufacturing capabilities, add new service offerings and accommodate its customers’ project timing requirements. The new facility will be called LSNE-Madison. Financial terms of the transaction were not disclosed.

LSNE-Madison is a 37,000 square foot multi-product facility that will be used for the manufacturing of final drug products for pre-clinical to Phase III/commercial use. The facility currently includes a high speed, automated aseptic fill line and a 144-square foot lyophilizer with existing space for additional equipment and the ability to expand to over 100,000 square feet of production space over time.

Click the PDF icon to download the full release or visit the LSNE website.

Share this page

Media contacts

Nina Suter
Head of Communications - Director
+44 (0) 207 632 1000
Brooke Gordon Sard Verbinnen & Co +1 212 687 8080

Related News & Views